Vincerx Pharma To Host Key Opinion Leader Webinar on VIP152 for the Treatment of Hematologic and Solid Tumors
February 24, 2021 08:00 ET
|
Vincerx, Inc.
PALO ALTO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
February 17, 2021 08:00 ET
|
Vincerx, Inc.
PALO ALTO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincera Pharma Announces Name Change to Vincerx
January 07, 2021 16:01 ET
|
Vincerx, Inc.
PALO ALTO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincera Pharma Announces Completion of Business Combination and Listing on Nasdaq
December 23, 2020 10:25 ET
|
Vincera Pharma, Inc.
Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020 Combined company renamed Vincera Pharma, Inc., common stock commences trading tomorrow, December 24,...
Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform
October 08, 2020 08:00 ET
|
Vincera Pharma, Inc.
Portfolio includes VIP152, a highly selective PTEFb/CDK9 inhibitor with encouraging Phase 1 monotherapy activity, including complete responses in DH-DLBCL Vincera intends to pursue multiple...